BRIEF: Heavily oversubscribed CF PharmTech triples in Hong Kong trading debut
Shares of pharmaceutical manufacturer CF PharmTech Inc. (2652.HK) roared out of the gate in their Hong Kong trading debut on Wednesday, opening up 219% before giving back some of the gains to close up 181% at HK$41.50 by the midday break.
The company sold 41.2 million shares for HK$14.75 apiece. The portion for local Hong Kong investors was oversubscribed by nearly 6,700 times, leading to just a 1% allocation probability for each lot application. The international portion was more than 11 times oversubscribed, with the overall share sale raising total net proceeds of HK$525 million ($67.3 million).
CF PharmTech develops and produces inhaled therapies, specializing in respiratory disorder treatments. Its revenue edged down 2.7% year-on-year to 136 million yuan in this year’s first quarter, even as its profit for the period more than doubled to 12.8 million yuan.
By Lau Chi Hang
To subscribe to Bamboo Works weekly free newsletter, click here
Related Articles
BRIEF: WeRide launches Hong Kong IPO to raise $400 million
BRIEF: Lufax replaces chief risk officer
BRIEF: Skyworth Digital profit tumbles 64% in first three quarters
BRIEF: EV maker Seres launches $1.7 billion IPO
RELATED ARTICLES
-
BRIEF: CF PharmTech to raise $77 million in Hong Kong IPO
2652.HK -
BRIEF: GenFleet shares double in heavily oversubscribed IPO
2595.HK
-
BRIEF: Dahon Tech rallies in hugely oversubscribed Hong Kong IPO
2543.HK
-
BRIEF: Hipine surges in Hong Kong trading debut
2583.HK
-
BRIEF: Butong shares jump in Hong Kong trading debut
9060.HK
-
BRIEF: Medtide rises in Hong Kong trading debut
3880.HK
-
BRIEF: Auntea Jenny surges in Hong Kong trading debut
2589.HK
